A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing–remitting multiple sclerosis (TIME MS)

Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple s...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Main Authors:	Remington, Gina M., Treadaway, Katherine, Frohman, Teresa, Salter, Amber, Stüve, Olaf, Racke, Michael K., Hawker, Kathleen, Agosta, Federica, Sormani, Maria Pia, Filippi, Massimo, Frohman, Elliot M.
Format:	Artigo
Sprog:	Inglês
Udgivet:	SAGE Publications 2010
Fag:	Original Research
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3002615/ https://ncbi.nlm.nih.gov/pubmed/21180632 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609355851
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing–remitting multiple sclerosis (TIME MS)

Lignende værker